Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Alzheimer's Disease clinical trials

Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 14, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
707
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Alzheimer's Disease studies are organized in the registry

The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Alzheimer's Disease. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 241–252 of 707 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Alzheimer Disease
Interventions
Self-Guided Lifestyle Intervention, Structured Lifestyle Intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 79 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
6
States / cities
Sacramento, California • Chicago, Illinois • Downers Grove, Illinois + 3 more
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Alzheimer Disease
Interventions
AL002, Placebo
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Rogers, Arkansas • Costa Mesa, California + 25 more
Conditions
Alzheimer Disease
Interventions
sabirnetug, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Carlsbad, California • Fullerton, California • Irvine, California + 40 more
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Florbetapir F 18 PET Scan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
77
States / cities
Anaheim, California • Imperial, California • Irvine, California + 59 more
Conditions
Alzheimer Disease, Early Onset Alzheimer Disease
Interventions
LX1001
Biological
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Maitland, Florida • Orlando, Florida • New York, New York + 1 more
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Canakinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Completed Not applicable Interventional Accepts healthy volunteers

Person-Environment Fit for Persons With Dementia

NCT05722743
Conditions
Dementia Alzheimers, Alzheimer Disease
Interventions
Harmony at HOME, National Institute on Aging Program
Behavioral
Lead sponsor
Elizabeth K Rhodus
Other
Eligibility
21 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-552, Placebo for ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Alamitos, California + 31 more
Completed Not applicable Interventional Accepts healthy volunteers

A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1

NCT06356337
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Light goggles, Daily reminder test message
Device · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Menands, New York
Completed Not applicable Interventional Results available

Efficacy of Gamification in Enhancing User Engagement

NCT05422339
Conditions
Alzheimer Disease, Dementia, Gamification, Assistive Technology
Interventions
The MapHabit system (MHS)
Device
Lead sponsor
MapHabit, Inc.
Industry
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Results available

Anti-viral Therapy in Alzheimer's Disease

NCT03282916
Conditions
Alzheimer Disease, Herpes Simplex 1, Herpes Simplex 2
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 95 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • New York, New York

About this Alzheimer's Disease clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.